Oral Complement Factor D Inhibitors for Selective Cascade Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The inappropriate activation of the complement system is implicated in various disease pathologies affecting the immune, renal, cardiovascular, and neurological systems, necessitating the development of effective complement inhibitors for therapeutic intervention.
Innovation Solution
Development of compounds with specific structures (Formulae I-IV) and their pharmaceutically acceptable salts, which act as inhibitors of the complement system to treat or prevent diseases characterized by aberrant complement activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complement proteins are activated to destroy pathogens, then pathogen elimination ability is improved, but healthy cells and tissue are destroyed
Solution Approach 1:
The patent introduces complement inhibitors as intermediary substances that selectively block the complement activation cascade. These inhibitors act as mediators between the immune system's pathogen-fighting mechanisms and healthy tissues, preventing the harmful effects on healthy cells while preserving the ability to eliminate pathogens through alternative pathways.
Solution Approach 2:
The invention modifies the activation parameters of the complement system by introducing compounds that change the threshold and kinetics of complement activation. By altering these parameters, the system can distinguish between pathogen-associated activation (which should proceed) and self-tissue activation (which should be inhibited), thereby resolving the contradiction between effective pathogen elimination and protection of healthy tissues.
2Power
If complement activation is enhanced to fight infection, then immune response effectiveness is improved, but inflammatory responses become uncontrolled
Solution Approach 1:
The patent employs feedback mechanisms through complement inhibitors that respond to activation signals. When complement activation reaches certain thresholds or persists beyond appropriate limits, the inhibitors are activated to provide negative feedback, thereby controlling inflammatory responses while preserving effective immune function during appropriate activation phases.
3Productivity
If complement cascade amplification is increased to rapidly destroy pathogens, then pathogen destruction speed is improved, but loss of control over activation increases
Solution Approach 1:
The invention applies preliminary action by introducing complement inhibitors before uncontrolled activation can occur. These inhibitors are positioned in advance to block hyperactive cascade amplification, allowing the complement system to maintain its rapid pathogen destruction capability while preventing runaway activation through pre-deployed regulatory mechanisms.
Data Source
AI summary
Disclosed are compounds of formula (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.